CX Institutional
UTHR icon

CX Institutional’s United Therapeutics UTHR Stock Holding History

CX Institutional’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-39
Closed -$21K – 1737
2026
Q2 		$21K Hold
39
– – ﹤0.01% 1172
2026
Q1 		$23K Buy
+39
New +$19.4K ﹤0.01% 1103

Other funds holding UTHR

AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Atwood & Palmer
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Polaris Capital Management
Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Livforsakringsbolaget Skandia
Livforsakringsbolaget Skandia Stockholm, Sweden $3.02B AUM 43.19% 1-Year Est. Return
Nepsis Inc
Nepsis Inc Minneapolis, Minnesota $317M AUM 37.22% 1-Year Est. Return

CX Institutional's UTHR Position: Q3 2026 in Review

CX Institutional sold out of United Therapeutics (UTHR) in Q3 2026, closing a stake of 39 shares — an estimated $21K sold.

CX Institutional first reported a position in UTHR in Q1 2026 and held it in 2 quarters. The position peaked at $23K in Q1 2026. 142 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • CX Institutional reported no remaining United Therapeutics position as of Q3 2026 after selling out during the quarter.
  • CX Institutional sold 39 United Therapeutics shares in Q3 2026, an estimated $21K.
  • CX Institutional first reported a position in United Therapeutics in Q1 2026 and held it in 2 quarters.
  • CX Institutional's United Therapeutics position peaked at $23K in Q1 2026.
  • 142 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.